Case Report: Acral vasculitis induced by Immune Checkpoint Inhibitors: a case series and literature review
Abstract
Introduction: Immune Checkpoint Inhibitors (ICIs) may cause various immune- related Adverse Events (irAEs). Of these events, vascular involvement is still considered an uncommon irAEs and generally concerns large or medium vessels. Acral small-vessel vasculitis can lead to severe digital necrosis.
Case presentation: Herein, we present three cases after treatment with pembrolizumab, nivolumab, and combination nivolumab/ipilimumab for lung adenocarcinoma, renal cell carcinoma, and melanoma, respectively. Two patients had a Raynaud's-like syndrome. All of them presented with digital ischemia of both hands and with severe acral necrosis in the first case. Management consisted in ICI discontinuation, high-dose steroids, and vasodilator agents with good evolution in the three cases. No rechallenge of ICI has been attempted.
Discussion: We found 12 other cases in the literature review to build a cohort of 15 patients, mostly male with a median age of 60 years. Lung cancer and melanoma are the most common tumors. The most frequently used ICI was pembrolizumab. The median time to onset was 8 weeks. The main clinical presentation was a distal and painful necrosis mostly on thehands with bilateral involvement. Toes were affected in only two cases. All cases were severe features with grade ≥ 3. Eleven patients were treated with steroids and vasodilator agents. ICI was discontinued permanently in all patients.
Conclusion: ICI-induced small-vessel vasculitis can lead to severe digital…
How strong is the evidence?
Evidence Hub reads this as a case series, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health. Reported size: 15 participants or records.
Read the paper
Related studies
- Drug repositioning: a brief overview
- Cyclic nucleotide phosphodiesterases in Drosophila melanogaster
- Time-resolved in silico modeling of fine-tuned cAMP signaling in platelets: feedback loops, titrated phosphorylations and pharmacological modulation
- Current View on Green Tea Catechins Formulations, Their Interactions with Selected Drugs, and Prospective Applications for Various Health Conditions
- In silico Structure-based Identification of Novel Acetylcholinesterase Inhibitors Against Alzheimer’s Disease
- Development and In Vitro Evaluation of Controlled Release Viagra® Containing Poloxamer-188 Using Gastroplus™ PBPK Modeling Software for In Vivo Predictions and Pharmacokinetic Assessments
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.